After racking up 41 Covid jab nods outside US, Novavax hits first profitable quarter but still disappoints investors

About four weeks before FDA’s outside advisors are slated to review Novavax’s Covid-19 jab after a long, federally-funded and winding journey that was all but Warp Speed in the US, Novavax provided an update on its first-quarter results.